Lodoxamide
Brand names: Alomide
Lodoxamide is a topical ophthalmic mast cell stabiliser used to treat allergic eye disorders, including vernal and seasonal allergic conjunctivitis and vernal keratoconjunctivitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It stabilises mast cells and prevents the antigen-stimulated release of histamine and other inflammatory mediators that drive the ocular allergic response.
Prescribing in practice
- Acts prophylactically rather than as a rescue treatment, so it should be used regularly and continuously to be effective and may take some days to produce symptomatic benefit.
- Contact lenses should not be worn during treatment of allergic conjunctivitis, and the preservative may be absorbed by soft lenses.
- Transient stinging or burning on instillation is common but usually settles.
Monitoring
Treatment is monitored clinically by reviewing symptom control and ocular comfort, with the drops continued throughout the period of allergen exposure.
Counselling the patient
- Use the drops regularly every day as prescribed, not just when symptoms flare, because they work by preventing reactions.
- Remove contact lenses before instilling and follow your clinician's advice on when they can be reworn.
- Mild stinging when you put the drops in is normal and short-lived.
Evidence & guidelines
Mast cell stabilisers are an established option for allergic conjunctivitis and their place in therapy is supported by ophthalmology guidance and the SPC.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- C-Peptide to Glucose Ratio · Diabetes Classification
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- HCT-CI — Haematopoietic Cell Transplant Comorbidity Index · Risk Stratification
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme